6-(2-chlorophenyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile | 147283-46-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-(2-chlorophenyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile
• 英文别名: 6-(2-chlorophenyl)pyrid-2-one-3-carbonitrile；6-(2-chlorophenyl)-2-oxo-1H-pyridine-3-carbonitrile
• CAS: 147283-46-3
• 化学式: C₁₂H₇ClN₂O
• 分子量: 230.653
• InChiKey: SSTNHBXIZOZHLP-UHFFFAOYSA-N

物化性质

• 沸点：
  468.3±45.0 °C(Predicted)
• 密度：
  1.38±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  52.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-(2-chlorophenyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile 在 palladium on activated charcoal 二苯基磷酸 、 氢溴酸 、 氢气 、 sodium methylate 、 sodium hydride 、 三乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 乙醇 、 溶剂黄146 为溶剂， 25.0 ℃ 、340.0 kPa 条件下， 反应 24.0h， 生成 2-(3-amino-2-oxo-6-phenyl-1,2-dihydro-1-pyridyl)-N-<2-<(tert-butyldimethylsilyl)oxy>-3,3,3-trifluoro-1-isopropylpropyl>acetamide
  参考文献：
  名称：

  Nonpeptidic Inhibitors of Human Leukocyte Elastase. 2. Design, Synthesis, and in vitro Activity of a Series of 3-Amino-6-aryl-2-oxopyridyl Trifluoromethyl Ketones

  摘要：

  A series of potent nonpeptidic inhibitors of the enzyme human leukocyte elastase (HLE) is reported. These inhibitors contain a 3-amino-2-pyridone ring as a central template in which the pyridone carbonyl and 3-position NH group are thought to form important hydrogen bonding interactions with the Val-216 residue of HLE. Substitution of the 6-position of the pyridone ring by various alkyl and aryl groups was found to afford increases in the in vitro potency of these inhibitors. A 6-position phenyl group, compound 10f, was found to result in a large increase in binding affinity, which was not obtained when the phenyl group was placed in either the 4- or 5-position of the molecule. Compound 10f was found to have good selectivity for HLE over other proteolytic enzymes, with the exception of bovine pancreatic chymotrypsin (BPC). Substitution of the 6-phenyl group in these molecules was found to decrease binding affinity for BPC without adversely affecting affinity for HLE.

  DOI：

  10.1021/jm00046a015
• 作为产物：
  描述：

  邻氯苯乙酮 在 sodium methylate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 16.5h， 生成 6-(2-chlorophenyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile
  参考文献：
  名称：

  WO2008/118414

  摘要：

  公开号：

文献信息

• Heterocyclic amides
  申请人：Zeneca Limited

  公开号：US05521179A1

  公开（公告）日：1996-05-28

  The present invention relates to certain novel heterocyclic amides which are 1-pyridylacetamide compounds of formula I, set out herein, which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes intermediates useful in the synthesis of these heterocyclic amides, processes for preparing the heterocyclic amides, pharmaceutical compositions containing such heterocyclic amides and methods for their use.

  本发明涉及某些新颖的杂环酰胺，它们是式I所示的1-吡啶乙酰胺化合物，这些化合物是人类白细胞弹性蛋白酶（HLE）的抑制剂，也被称为人类中性粒细胞弹性蛋白酶（HNE），使它们在需要这种抑制作用时非常有用，例如用作药理学、诊断和相关研究工具以及治疗哺乳动物中HLE相关疾病。该发明还包括在合成这些杂环酰胺过程中有用的中间体，制备这些杂环酰胺的方法，含有这些杂环酰胺的药物组合物以及它们的使用方法。
• Certain pyridyl ketones for treating diseases involving leukocyte
  申请人：Zeneca Limited

  公开号：US05486529A1

  公开（公告）日：1996-01-23

  The present invention relates to certain novel heterocyclic ketones which are 1-pyridylacetamide ketones of formula I, set out herein, which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes intermediates useful in the synthesis of these heterocyclic ketones, processes for preparing the heterocyclic ketones, pharmaceutical compositions containing such heterocyclic ketones and methods for their use.

  本发明涉及某些新颖的杂环酮，这些酮是式I所示的1-吡啶基乙酰胺酮，该酮是人类白细胞弹性蛋白酶（HLE）的抑制剂，也被称为人类中性粒细胞弹性蛋白酶（HNE），使其在需要抑制时具有用处，例如用作药物学、诊断和相关研究工具以及治疗哺乳动物中HLE涉及的疾病。该发明还包括合成这些杂环酮的中间体，制备杂环酮的方法，含有这种杂环酮的药物组合物以及其使用方法。
• SUBSTITUTED PYRIDO[3,2-E][1,2,4]TRIAZOLO[4,3-C]PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS
  申请人：Debenham John S.

  公开号：US20100029697A1

  公开（公告）日：2010-02-04

  Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer s disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and the promotion of wakefulness.

  结构式（I）的新化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗、预防和抑制由CB1受体介导的疾病。本发明的化合物可用作中枢作用药物，用于治疗精神病、记忆障碍、认知障碍、阿尔茨海默病、偏头痛、神经病、神经炎性疾病（包括多发性硬化症和格林-巴利综合征）以及病毒性脑炎、脑血管意外和头部创伤的炎症后遗症、焦虑症、压力、癫痫、帕金森病、运动障碍和精神分裂症。这些化合物还可用于治疗物质滥用障碍、肥胖症或进食障碍的治疗，以及哮喘、便秘、慢性肠假性梗阻、肝硬化、非酒精性脂肪肝病（NAFLD）、非酒精性脂肪性肝炎（NASH）和促进清醒。
• Heterocyclic amides having HLE inhibiting activity
  申请人：ZENECA LIMITED

  公开号：EP0509769A2

  公开（公告）日：1992-10-21

  The present invention relates to certain novel heterocyclic amides which are 1-pyridylacetamide compounds of formula I, set out herein, which are inhibitors of human leukocyte elastase (HLE), also known as human neutrophil elastase (HNE), making them useful whenever such inhibition is desired, such as for research tools in pharmacological, diagnostic and related studies and in the treatment of diseases in mammals in which HLE is implicated. The invention also includes intermediates useful in the synthesis of these heterocyclic amides, processes for preparing the heterocyclic amides, pharmaceutical compositions containing such heterocyclic amides and methods for their use.

  本发明涉及某些新型杂环酰胺，它们是式I的1-吡啶基乙酰胺化合物，载于本发明中，它们是人白细胞弹性蛋白酶（HLE），也称为人中性粒细胞弹性蛋白酶（HNE）的抑制剂，使得它们在任何需要这种抑制的情况下都有用，例如在药理学、诊断学和相关研究中用作研究工具，以及在治疗哺乳动物中涉及HLE的疾病时。本发明还包括用于合成这些杂环酰胺的中间体、制备杂环酰胺的工艺、含有这些杂环酰胺的药物组合物及其使用方法。
• Pyridopyrimidine based cannabinoid-1 receptor inverse agonists: Synthesis and biological evaluation
  作者：John S. Debenham、Christina B. Madsen-Duggan、Junying Wang、Xinchun Tong、Julie Lao、Tung M. Fong、Marie-Therese Schaeffer、Jing Chen Xiao、Cathy C.R.-R. Huang、Chun-Pyn Shen、D. Sloan Stribling、Lauren P. Shearman、Alison M. Strack、D. Euan MacIntyre、Jeffrey J. Hale、Thomas F. Walsh

  DOI：10.1016/j.bmcl.2009.03.005

  日期：2009.5

  The synthesis, SAR and binding affinities are described for cannabinoid-1 receptor (CB1R) specific inverse agonists based on pyridopyrimidine and heterotricyclic scaffolds. Food intake and pharmacokinetic evaluation of several of these compounds indicate that they are effective orally active modulators of CB1R. (C) 2009 Elsevier Ltd. All rights reserved.